Back HIV/AIDS

HIV / AIDS

FDA Approves ViiV Single-Tablet Regimen Containing Dolutegravir

ViiV Healthcare announced this week that the U.S. Food and Drug Administration (FDA) has approved its all-in-1 antiretroviral fixed-dose combination pill containing the HIV integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (the drugs in Epzicom or Kivexa). The new coformulation -- with the brand name Triumeq -- is the first single-tablet regimen that does not contain tenofovir and emtricitabine, making it an option for people with impaired kidney function. HLA-B*5701 genetic screening should be done prior to starting Triumeq to test for abacavir hypersensitivity. [Editor's note: On September 3 ViiV announced that the European Commission has also approved Triumeq.]

alt

AIDS 2014: Disappointing HIV Cure News Leads to New Questions

The fourth IAS Towards an HIV Cure symposium -- an initiative of the International AIDS Society -- took place July 19-20, prior to the 20th International AIDS Conference in Melbourne.

alt

AIDS 2014: Global ART Demand Projected to Reach 16.8 Million by 2016

The projected demand for antiretroviral therapy (ART) will increase to 16.8 million person-years by the end of 2016 in low- and middle-income countries, including 15.7 million person-years of adult and 1.1 million person-years of pediatric formulations, according to a study presented on behalf of the global ARV Forecasting Technical Working Group at the 20th International AIDS Conference(AIDS 2014) last month in Melbourne.

alt

AIDS 2014: Criminalization Decreases HIV Prevention and Treatment Among Gay Men [VIDEO]

Gay and bisexual men who have been arrested or persecuted for same-sex activity are less likely to access HIV prevention services, and those who are HIV positive are less likely to receive antiretroviral treatment, according to a study presented at the 20th International AIDS Conference last month in Melbourne.

alt

AIDS 2014: HIV Prevention for Gay Men Differs Between San Francisco and London

A study presented at the 20th International AIDS Conference last month in Melbourne compared HIV epidemics among gay and bisexual men in San Francisco and London, confirming that while HIV incidence in San Francisco was falling, it was static and even rising in London. HIV is increasing among gay men in London because of a lack of testing, the research suggests, while testing is enabling more disclosure and effective serosorting in San Francisco.

alt

AIDS 2014: Worldwide Adolescent AIDS Deaths Rising, Especially Among Boys

While new HIV infections have declined among children, adolescents, and adults since 2000, HIV-related deaths have risen sharply among adolescents, especially 15- to 19-year-old males, Tyler Porth of UNICEF reported at the 20th International AIDS Conference last month in Melbourne.

alt

AIDS 2014: Increased ART for Mothers Does Not Guarantee Optimal Care for Infants

The significant increase in access to antiretroviral therapy (ART) for all pregnant women living with HIV in Malawi after implementation of Option B+ contrasts with low coverage of early diagnosis and uptake of cotrimoxazole prophylaxis for HIV-exposed infants, Priscilla Idele of UNICEF reported at the 20th International AIDS Conference (AIDS 2014) last month in Melbourne.

alt